Journal of Neuroscience,
Год журнала:
2020,
Номер
40(39), С. 7559 - 7576
Опубликована: Авг. 31, 2020
Degeneration
of
locus
Coeruleus
(LC)
neurons
and
dysregulation
noradrenergic
signaling
are
ubiquitous
features
Parkinson9s
disease
(PD).
The
LC
is
among
the
first
brain
regions
affected
by
α-synuclein
(asyn)
pathology,
yet
how
asyn
affects
these
remains
unclear.
LC-derived
norepinephrine
(NE)
can
stimulate
neuroprotective
mechanisms
modulate
immune
cells,
while
NE
neurotransmission
may
exacerbate
progression,
particularly
nonmotor
symptoms,
contribute
to
chronic
neuroinflammation
associated
with
PD
pathology.
Although
transgenic
mice
overexpressing
have
previously
been
developed,
transgene
expression
usually
driven
pan-neuronal
promoters
thus
has
not
selectively
targeted
neurons.
Here
we
report
a
novel
mouse
expressing
human
wild-type
under
control
noradrenergic-specific
dopamine
β-hydroxylase
promoter
(DBH-hSNCA).
These
developed
oligomeric
conformation-specific
in
neurons,
alterations
hippocampal
microglial
abundance,
upregulated
GFAP
expression,
degeneration
fibers,
decreased
striatal
DA
metabolism,
age-dependent
behaviors
reminiscent
symptoms
that
were
rescued
adrenergic
receptor
antagonists.
provide
insights
into
pathology
central
dysfunction
early
pathophysiology.
SIGNIFICANCE
STATEMENT
ɑ-Synuclein
loss
two
most
neuropathologic
Dysregulated
PD,
including
sleep
disturbances,
emotional
changes
such
as
anxiety
depression,
cognitive
decline.
Importantly,
inflammation
in,
progression
of,
PD.
We
generated
investigate
increased
function
transmission
behaviors.
cytotoxic
effects
asyn,
astrogliosis,
fiber
degeneration,
disruptions
without
inclusions.
Journal of Alzheimer s Disease,
Год журнала:
2021,
Номер
83(1), С. 5 - 22
Опубликована: Июль 3, 2021
The
locus
coeruleus
(LC),
a
tiny
nucleus
in
the
brainstem
and
principal
site
of
noradrenaline
synthesis,
has
major
role
regulating
autonomic
function,
arousal,
attention,
neuroinflammation.
LC
dysfunction
been
linked
to
range
disorders;
however
particular
interest
is
given
it
plays
Alzheimer’s
disease
(AD).
undergoes
significant
neuronal
loss
AD,
thought
occur
early
process.
While
also
suggested
aging,
this
relationship
less
clear
as
findings
have
contradictory.
density
be
indicative
cognitive
reserve
evidence
for
these
claims
will
discussed.
Recent
imaging
techniques
allowing
visualization
vivo
using
neuromelanin-sensitive
MRI
are
developing
our
understanding
aging
AD.
Tau
pathology
within
evident
at
an
age
most
individuals;
however,
between
tau
accumulation
why
some
individuals
then
develop
AD
not
understood.
Neuromelanin
pigment
accumulates
cells
with
proposed
toxic
inflammatory
when
released
into
extracellular
environment.
This
review
explore
current
knowledge
changes
both
from
postmortem,
imaging,
experimental
studies.
We
discuss
reasons
behind
susceptibility
loss,
focus
on
neuromelanin
neuroinflammation
caused
by
LC-noradrenaline
pathway.
Proceedings of the National Academy of Sciences,
Год журнала:
2019,
Номер
116(52), С. 26224 - 26229
Опубликована: Дек. 23, 2019
Alzheimer's
disease
(AD)
is
a
progressive
neurodegenerative
disorder
that
the
sixth
leading
cause
of
death
and
most
common
dementia
worldwide.
Over
last
few
decades,
significant
advancements
have
been
made
in
our
understanding
AD
by
investigating
molecular
mechanisms
underlying
amyloid-β
tau
pathology.
Despite
this
progress,
no
disease-modifying
treatments
exist
for
AD,
an
issue
will
exacerbated
rising
costs
prevalence
disorder.
Moreover,
effective
therapies
to
address
devastating
cognitive
behavioral
symptoms
are
also
urgently
needed.
This
perspective
focuses
on
value
nonhuman
primate
(NHP)
models
bridging
molecular,
circuit,
levels
analysis
better
understand
complex
genetic
environmental/lifestyle
factors
contribute
pathogenesis.
These
investigations
could
provide
opportunity
translating
pathogenesis
physiological
related
disorders
into
new
diagnostic
approaches
prevent
or
restore
brain
function
symptomatic
individuals.
Brain,
Год журнала:
2021,
Номер
145(6), С. 1924 - 1938
Опубликована: Дек. 14, 2021
Abstract
The
locus
coeruleus
is
the
initial
site
of
Alzheimer’s
disease
neuropathology,
with
hyperphosphorylated
Tau
appearing
in
early
adulthood
followed
by
neurodegeneration
dementia.
Locus
dysfunction
contributes
to
pathobiology
experimental
models,
which
can
be
rescued
increasing
norepinephrine
transmission.
To
test
augmentation
as
a
potential
disease-modifying
therapy,
we
performed
biomarker-driven
phase
II
trial
atomoxetine,
clinically-approved
transporter
inhibitor,
subjects
mild
cognitive
impairment
due
disease.
design
was
single-centre,
12-month
double-blind
crossover
trial.
Thirty-nine
participants
and
biomarker
evidence
were
randomized
atomoxetine
or
placebo
treatment.
Assessments
collected
at
baseline,
6-
(crossover)
12-months
(completer).
Target
engagement
assessed
CSF
plasma
measures
metabolites.
Prespecified
primary
outcomes
levels
IL1α
TECK.
Secondary/exploratory
included
clinical
measures,
analyses
amyloid-β42,
Tau,
pTau181,
mass
spectrometry
proteomics
immune-based
targeted
inflammation-related
cytokines,
well
brain
imaging
MRI
fluorodeoxyglucose-PET.
Baseline
demographic
similar
across
arms.
Dropout
rates
5.1%
for
2.7%
placebo,
no
significant
differences
adverse
events.
Atomoxetine
robustly
increased
levels.
IL-1α
TECK
not
measurable
most
samples.
There
treatment
effects
on
cognition
outcomes,
expected
given
short
duration.
associated
reduction
pTau181
compared
but
change
amyloid-β42.
also
significantly
altered
abundances
protein
panels
linked
pathophysiologies,
including
synaptic,
metabolism
glial
immunity,
CDCP1,
CD244,
TWEAK
osteoprotegerin
proteins.
Treatment
brain-derived
neurotrophic
factor
reduced
triglycerides
plasma.
Resting
state
functional
showed
inter-network
connectivity
between
insula
hippocampus.
Fluorodeoxyglucose-PET
atomoxetine-associated
uptake
hippocampus,
parahippocampal
gyrus,
middle
temporal
pole,
inferior
gyrus
fusiform
carry-over
6
months
after
In
summary,
safe,
tolerated
achieved
target
prodromal
pTau,
normalized
synaptic
function,
activity
key
lobe
circuits.
Further
study
warranted
repurposing
drug
slow
progression.
Alzheimer s & Dementia,
Год журнала:
2023,
Номер
19(5), С. 2182 - 2196
Опубликована: Янв. 15, 2023
Abstract
The
neuromodulatory
subcortical
system
(NSS)
nuclei
are
critical
hubs
for
survival,
hedonic
tone,
and
homeostasis.
Tau‐associated
NSS
degeneration
occurs
early
in
Alzheimer's
disease
(AD)
pathogenesis,
long
before
the
emergence
of
pathognomonic
memory
dysfunction
cortical
lesions.
Accumulating
evidence
supports
role
behavioral
neuropsychiatric
manifestations
featured
AD.
Experimental
studies
even
suggest
that
AD‐associated
drives
brain
neuroinflammatory
status
contributes
to
progression,
including
exacerbation
Given
important
pathophysiologic
etiologic
roles
involve
AD
stages,
there
is
an
urgent
need
expand
our
understanding
mechanisms
underlying
vulnerability
more
precisely
detail
clinical
progression
changes
Here,
Professional
Interest
Area
International
Society
Advance
Research
Treatment
highlights
knowledge
gaps
about
within
provides
recommendations
priorities
specific
research,
biomarker
development,
modeling,
intervention.
Highlights
Neuromodulatory
degenerate
pathological
stages.
pathophysiology
exacerbated
by
degeneration.
symptoms
dementia.
Biomarkers
integrity
would
be
value‐creating
dementia
care.
present
strategic
prospects
disease‐modifying
therapies.
Nature Aging,
Год журнала:
2024,
Номер
4(5), С. 625 - 637
Опубликована: Апрель 25, 2024
Abstract
Autopsy
studies
indicated
that
the
locus
coeruleus
(LC)
accumulates
hyperphosphorylated
tau
before
allocortical
regions
in
Alzheimer’s
disease.
By
combining
vivo
longitudinal
magnetic
resonance
imaging
measures
of
LC
integrity,
positron
emission
tomography
and
cognition
with
autopsy
data
transcriptomic
information,
we
examined
whether
changes
precede
deposition
specific
genetic
features
underlie
LC’s
selective
vulnerability
to
tau.
We
found
integrity
preceded
medial
temporal
lobe
accumulation,
together
these
processes
were
associated
lower
cognitive
performance.
Common
gene
expression
profiles
between
LC–medial
lobe–limbic
map
biological
functions
protein
transport
regulation.
These
findings
advance
our
understanding
spatiotemporal
patterns
initial
spreading
from
disease
pathology.
can
be
a
promising
indicator
for
identifying
time
window
when
individuals
are
at
risk
progression
underscore
importance
interventions
mitigating
spread.
Journal of Neuroscience,
Год журнала:
2018,
Номер
38(48), С. 10255 - 10270
Опубликована: Окт. 15, 2018
Brainstem
locus
ceruleus
neurons
(LCn)
are
among
the
first
across
lifespan
to
evidence
tau
pathology,
and
LCn
implicated
in
propagation
throughout
cortices.
Yet,
events
influencing
poorly
understood.
Activated
persistently
wakefulness,
experience
significant
metabolic
stress
response
chronic
short
sleep
(CSS).
Here
we
explored
whether
CSS
influences
biochemical,
neuroanatomical,
and/or
behavioral
progression
of
tauopathy
male
female
P301S
mice.
early
adult
life
advanced
temporal
neurobehavioral
impairments
resulted
a
lasting
increase
soluble
oligomers.
Intriguingly,
an
AT8
MC1
pathology
LC.
Over
time
including
tangles,
was
evident
forebrain
tau-vulnerable
regions.
Sustained
microglial
astrocytic
activation
observed
as
well.
Remarkably,
loss
two
regions
examined:
basolateral
amygdala
A
second,
distinct
form
disruption,
fragmentation
sleep,
during
also
increased
deposition
imparted
impairment.
Collectively,
findings
demonstrate
that
disruption
has
important
effects
on
mice,
hastening
neurodegeneration,
neuroinflammation,
impairments.
SIGNIFICANCE
STATEMENT
Chronic
(CSS)
is
pervasive
modern
society.
Here,
found
behavioral,
neuroanatomic
aspects
mouse
model
mutation.
Specifically,
hastened
onset
motor
impairment
greater
both
basolateral/lateral
amygdala.
Importantly,
despite
protracted
recovery
opportunity
after
CSS,
mice
evidenced
sustained
pathogenic
oligomers,
limbic
system
nuclei.
These
unveil
habits
determinant
tauopathy.
Neurobiology of Disease,
Год журнала:
2020,
Номер
146, С. 105089 - 105089
Опубликована: Сен. 22, 2020
Adrenergic
systems
regulate
both
cognitive
function
and
immune
function.
The
primary
source
of
adrenergic
signaling
in
the
brain
is
norepinephrine
(NE)
neurons
locus
coeruleus
(LC),
which
are
vulnerable
to
age-related
degeneration
one
earliest
sites
pathology
neurodegenerative
disorders
such
as
Alzheimer's
Disease
(AD).
Loss
tone
may
potentiate
neuroinflammation
aging
conditions.
Importantly,
beta-blockers
(beta-adrenergic
antagonists)
a
common
treatment
for
hypertension,
co-morbid
with
aging,
further
exacerbate
associated
loss
central
nervous
system
(CNS).
present
studies
were
designed
examine
proinflammatory
consequences
beta-blocker
administration
an
acute
lipopolysaccharide
(LPS)
model
well
chronic
effects
on
behavior
amyloid-beta
protein
precursor
(APP)
mouse
AD.
We
provide
evidence
robust
potentiation
peripheral
inflammation
4
different
LPS.
However,
did
not
CNS
this
model.
Notably,
same
model,
genetic
knockdown
either
beta1-
or
beta2-adrenergic
receptors
microglia
inflammation.
Furthermore,
APP
amyloid
pathology,
beta-blocker,
metoprolol,
also
induced
markers
phagocytosis
impaired
wild-type
mice.
Given
induction
vivo,
we
examined
synaptosomes
vitro
culture
showed
that
enhanced
whereas
beta-adrenergic
agonists
inhibited
synaptosomes.
In
conclusion,
potentiated
peripherally
systemic
centrally
amyloidosis
neuroinflammation.
Additionally,
learning
memory
modulated
synaptic
implications
degeneration.
These
findings
warrant
consideration
administration,
restricted
periphery
patients
disorders.
Journal of Neuroscience Research,
Год журнала:
2020,
Номер
98(12), С. 2406 - 2434
Опубликована: Сен. 1, 2020
Abstract
Locus
coeruleus
(LC)
is
the
main
noradrenergic
(NA)
nucleus
of
central
nervous
system.
LC
degenerates
early
during
Alzheimer's
disease
(AD)
and
NA
loss
might
concur
to
AD
pathogenesis.
Aside
from
neurons,
terminals
provide
dense
innervation
brain
intraparenchymal
arterioles/capillaries,
modulates
astrocyte
functions.
The
term
neurovascular
unit
(NVU)
defines
strict
anatomical/functional
interaction
occurring
between
glial
cells,
vessels.
NVU
plays
a
fundamental
role
in
coupling
energy
demand
activated
regions
with
regional
cerebral
blood
flow,
it
includes
blood–brain
barrier
(BBB),
an
active
neuroinflammation,
participates
also
glymphatic
alteration
involved
pathophysiology
through
several
mechanisms,
mainly
related
relative
oligoemia
impairment
structural
functional
BBB
integrity,
which
contributes
intracerebral
accumulation
insoluble
amyloid.
We
review
existing
data
on
morphological
features
LC‐NA
NVU,
as
well
its
contribution
proper
functioning.
After
introducing
experimental
linking
AD,
have
repeatedly
shown
key
neuroinflammation
increased
amyloid
plaque
formation,
we
discuss
potential
mechanisms
by
modulation
contribute
Surprisingly,
thus
far
not
so
many
studies
tested
directly
these
models
has
been
lesioned
experimentally.
Clarifying
pathogenesis
may
disclose
therapeutic
targets
for
AD.